Diversified Trust Co Cuts Position in Johnson & Johnson (NYSE:JNJ)

Diversified Trust Co lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 22.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,569 shares of the company’s stock after selling 27,468 shares during the quarter. Diversified Trust Co’s holdings in Johnson & Johnson were worth $15,276,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in JNJ. Keener Financial Planning LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $40,000. WFA Asset Management Corp boosted its holdings in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $44,000. Disciplined Equity Management Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $45,000. Finally, Grayhawk Investment Strategies Inc. boosted its holdings in shares of Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Morgan Stanley decreased their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Bank of America decreased their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE JNJ opened at $146.03 on Wednesday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The business has a fifty day simple moving average of $148.09 and a two-hundred day simple moving average of $153.97. The firm has a market cap of $351.45 billion, a PE ratio of 9.10, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period in the previous year, the company posted $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a $1.24 dividend. The ex-dividend date was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.40%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.